Funding Opportunities
RNA Pilot Grant Program Fall 2026
The Penn Institute for RNA Innovation at the University of Pennsylvania, CHOP, and Wistar seeks to support RNA-related basic, translational and clinical research. Towards that goal, the Institute is requesting applications for its Pilot Grants Program for Fall 2026. Pilot funding will provide initial support to establish proof of concept or extend findings to enable extramural funding and publications in the future. Given changes in funding priorities at NIH this Pilot award will also be available for existing RNA-related projects that are being modified to bridge to new scientific areas that align with priority areas of the RNA Institute. These priority areas are indicated below along with, deadlines, and application guidelines.
The Fall 2026 Pilot Grant Program research priority areas will be to support:
- Cross-disciplinary research that will lead to extramurally funded research in either basic or translational science in the arena of RNA biology. Applications related to vaccine research involving RNA are welcome.
- Supplements to existing projects involving RNA basic or translational science in which a change in direction is planned for the project to align with emerging NIH priorities
- Early- and mid-stage investigators undertaking new projects involving basic or translational RNA technology and for whom alternative resources for funding are not available.
Prior recipients of pilot awards from the RNA Institute are eligible to apply for new awards in different areas. Prior awardees may also apply for funds to extend research from a previous pilot award and will be judged based on progress made during the first funding period.
Applicants are encouraged to utilize shared resource core facilities and services provided by the RNA Institute and Penn’s Artificial Intelligence-driven RNA BioFoundry (AIRFoundry) including the mRNA Core, Targeting Core and affiliated Cores (High-throughput Screening Core, Beckman Cryo-EM Center, and Structural Biology Core).
We encourage applicants to consult with our Core Directors or any members of the Institute’s Leadership Group early in the preparation of their application. Allocation of Core effort to assist in grant preparation will be available on a first-come first-served basis.
Scientific areas for applications to address:
RNA Basic Science: RNA processing, RNA binding proteins, noncoding RNAs, and nucleoside-modifications are encouraged along with the development of tools to further the use of RNA technology in the treatment of disease.
Translational Science: RNA-based science relevant to prevention, diagnostics, and therapeutics for human diseases. Projects and teams that bridge laboratory-based research to pre-clinical studies or models and/or that extend clinical observations to the laboratory (addressing mechanisms, identifying therapeutic targets, and developing novel interventions) are strongly encouraged to apply.
We hope you will consider this opportunity to creatively apply RNA-based approaches to new and exciting questions in your research.
Program Timeline
|
Event |
Date |
|---|---|
|
Application deadline |
October 27, 2026, by11:59 p.m. |
|
Decisions communicated to applicants |
December 2026 |
|
Funding begins |
January 1, 2027 |
Eligibility
Principal Investigators (PIs) for awards must have a faculty appointment at the University of Pennsylvania, Children’s Hospital of Philadelphia, or the Wistar Institute and hold the rank of Assistant, Associate or Full Professor, Research Professor, or Instructor. Postdoctoral trainees are also encouraged to apply, provided that a faculty sponsor includes a Letter of Support for the trainee in the application.
Proposals may not describe the same specific research that is funded by other sources during the grant period.
Budget and Duration
Individual applicants may request budgets up to $50,000 in direct costs and may propose projects lasting up to 12 months. The total equipment budget must not exceed $10,000.
Application Requirements and Procedures
Full applications must be uploaded no later than October 27, 2026, by 11:59pm as a single PDF file. Please label the file as PIFullName_PilotFall2026.pdf and include the following materials:
a. Cover Letter: A brief cover letter from the PI containing the title of the proposal and describing the value of the project and a statement that all collaborators listed on the application agree with the proposal.
b. Abstract: A brief abstract of no more than 250 words.
c. NIH Biosketch: An NIH format biosketch must be submitted for the PI and Co-Is.
d. Proposal: The research proposal should be two single-spaced pages with one-inch margins and should include the essential background information related to the project. Inclusion of preliminary data is welcomed but not required. Please use Arial size 11 font. References should be attached to your research proposal and will not count toward your page limit. Please provide a timeline of implementation to ensure meeting all milestones by the end of the funding period.
e. Budget: Please use the template budget page and provide detailed expenses. Salary support for faculty is discouraged.
f. Budget Justification: Please provide a short justification for all personnel, supplies, and equipment that will be expensed to this project. Please indicate the importance of this funding to the feasibility of your research proposal. Please indicate if any other funds are available to you for the proposed research.
Submit your application. After your submission is complete, you will receive a confirmation receipt by email.
Eligibility and appropriate project support will be determined by the Institute for RNA Innovation. The application must have RNA-related research as its focus and currently not be funded by other sources.
Review Criteria
A peer review panel composed of faculty with a range of expertise will be responsible for award decisions, evaluating eligible applications competitively. The primary factors in award decisions will be the scientific merit of the proposed research and the long-term promise of the proposed research. Upon request, applicants may receive partial critiques of their proposals. All applicants will receive a review outcome indicating one of the following: “Funded,” “Not Funded,” or “Not Eligible.”
Grant Recipient Requirements
Copies of IACUC and IRB approvals will be required if an award is funded.
Those receiving a grant will be expected to become active members of the Institute for RNA Innovation research community. Both the PIs and those working on funded projects are expected to:
- Acknowledge Institute for RNA Innovation Support in publications. Any publications that are a direct result of
- this funding must reference: “Supported in part by the Institute for RNA Innovation of the Perelman School of Medicine at the University of Pennsylvania.”
- Self-identify as a member of the Institute for RNA Innovation on all publications emanating from the work supported by this grant.
- Use awarded funds solely to support the RNA research described in their proposal.
- Provide a progress report 30 days after the end of funding.
- Contribute a presentation on research accomplishments at a future talk/symposium hosted by the Institute for RNA Innovation.
- Provide follow-up information regarding the long-term impact of the award(s) on your overall research program and funding.
Questions?
Contact: Jill Agolino
2026
RNA Pilot Grant Program Fall 2026
The Penn Institute for RNA Innovation at the University of Pennsylvania, CHOP, and Wistar seeks to support RNA-related basic, translational and clinical research. Towards that goal, the Institute is requesting applications for its Pilot Grants Program for Fall 2026. Pilot funding will provide initial support to establish proof of concept or extend findings to enable extramural funding and publications in the future. Given changes in funding priorities at NIH this Pilot award will also be available for existing RNA-related projects that are being modified to bridge to new scientific areas that align with priority areas of the RNA Institute. These priority areas are indicated below along with, deadlines, and application guidelines.
The Fall 2026 Pilot Grant Program research priority areas will be to support:
- Cross-disciplinary research that will lead to extramurally funded research in either basic or translational science in the arena of RNA biology. Applications related to vaccine research involving RNA are welcome.
- Supplements to existing projects involving RNA basic or translational science in which a change in direction is planned for the project to align with emerging NIH priorities
- Early- and mid-stage investigators undertaking new projects involving basic or translational RNA technology and for whom alternative resources for funding are not available.
Prior recipients of pilot awards from the RNA Institute are eligible to apply for new awards in different areas. Prior awardees may also apply for funds to extend research from a previous pilot award and will be judged based on progress made during the first funding period.
Applicants are encouraged to utilize shared resource core facilities and services provided by the RNA Institute and Penn’s Artificial Intelligence-driven RNA BioFoundry (AIRFoundry) including the mRNA Core, Targeting Core and affiliated Cores (High-throughput Screening Core, Beckman Cryo-EM Center, and Structural Biology Core).
We encourage applicants to consult with our Core Directors or any members of the Institute’s Leadership Group early in the preparation of their application. Allocation of Core effort to assist in grant preparation will be available on a first-come first-served basis.
Scientific areas for applications to address:
RNA Basic Science: RNA processing, RNA binding proteins, noncoding RNAs, and nucleoside-modifications are encouraged along with the development of tools to further the use of RNA technology in the treatment of disease.
Translational Science: RNA-based science relevant to prevention, diagnostics, and therapeutics for human diseases. Projects and teams that bridge laboratory-based research to pre-clinical studies or models and/or that extend clinical observations to the laboratory (addressing mechanisms, identifying therapeutic targets, and developing novel interventions) are strongly encouraged to apply.
We hope you will consider this opportunity to creatively apply RNA-based approaches to new and exciting questions in your research.
Program Timeline
|
Event |
Date |
|---|---|
|
Application deadline |
October 27, 2026, by11:59 p.m. |
|
Decisions communicated to applicants |
December 2026 |
|
Funding begins |
January 1, 2027 |
Eligibility
Principal Investigators (PIs) for awards must have a faculty appointment at the University of Pennsylvania, Children’s Hospital of Philadelphia, or the Wistar Institute and hold the rank of Assistant, Associate or Full Professor, Research Professor, or Instructor. Postdoctoral trainees are also encouraged to apply, provided that a faculty sponsor includes a Letter of Support for the trainee in the application.
Proposals may not describe the same specific research that is funded by other sources during the grant period.
Budget and Duration
Individual applicants may request budgets up to $50,000 in direct costs and may propose projects lasting up to 12 months. The total equipment budget must not exceed $10,000.
Application Requirements and Procedures
Full applications must be uploaded no later than October 27, 2026, by 11:59pm as a single PDF file. Please label the file as PIFullName_PilotFall2026.pdf and include the following materials:
a. Cover Letter: A brief cover letter from the PI containing the title of the proposal and describing the value of the project and a statement that all collaborators listed on the application agree with the proposal.
b. Abstract: A brief abstract of no more than 250 words.
c. NIH Biosketch: An NIH format biosketch must be submitted for the PI and Co-Is.
d. Proposal: The research proposal should be two single-spaced pages with one-inch margins and should include the essential background information related to the project. Inclusion of preliminary data is welcomed but not required. Please use Arial size 11 font. References should be attached to your research proposal and will not count toward your page limit. Please provide a timeline of implementation to ensure meeting all milestones by the end of the funding period.
e. Budget: Please use the template budget page and provide detailed expenses. Salary support for faculty is discouraged.
f. Budget Justification: Please provide a short justification for all personnel, supplies, and equipment that will be expensed to this project. Please indicate the importance of this funding to the feasibility of your research proposal. Please indicate if any other funds are available to you for the proposed research.
Submit your application. After your submission is complete, you will receive a confirmation receipt by email.
Eligibility and appropriate project support will be determined by the Institute for RNA Innovation. The application must have RNA-related research as its focus and currently not be funded by other sources.
Review Criteria
A peer review panel composed of faculty with a range of expertise will be responsible for award decisions, evaluating eligible applications competitively. The primary factors in award decisions will be the scientific merit of the proposed research and the long-term promise of the proposed research. Upon request, applicants may receive partial critiques of their proposals. All applicants will receive a review outcome indicating one of the following: “Funded,” “Not Funded,” or “Not Eligible.”
Grant Recipient Requirements
Copies of IACUC and IRB approvals will be required if an award is funded.
Those receiving a grant will be expected to become active members of the Institute for RNA Innovation research community. Both the PIs and those working on funded projects are expected to:
- Acknowledge Institute for RNA Innovation Support in publications. Any publications that are a direct result of
- this funding must reference: “Supported in part by the Institute for RNA Innovation of the Perelman School of Medicine at the University of Pennsylvania.”
- Self-identify as a member of the Institute for RNA Innovation on all publications emanating from the work supported by this grant.
- Use awarded funds solely to support the RNA research described in their proposal.
- Provide a progress report 30 days after the end of funding.
- Contribute a presentation on research accomplishments at a future talk/symposium hosted by the Institute for RNA Innovation.
- Provide follow-up information regarding the long-term impact of the award(s) on your overall research program and funding.
Questions?
Contact: Jill Agolino
RNA Travel Grant Program
The Institute for RNA Innovation at the University of Pennsylvania, CHOP, and Wistar seeks to support RNA biology research to enhance basic science, translational, and clinical studies.
Travel Grants support graduate students and postdoctoral researchers who wish to attend and/or present their research at scholarly meetings off campus and may be used to defray the cost of travel and fees.
Eligibility
- Applying graduate student or postdoctoral researcher must be mentored by a member of the Institute for RNA Innovation.
- Must be attending a major regional, national, or international conference.
- Must have travel authorization from their department prior to travel.
- Cannot have received a prior travel grant during the academic year.
- Cannot have received more than 2 prior travel grants during their tenure at Penn.
Budget
Grants may be awarded to graduate students or postdoctoral researchers who are attending and/or presenting a research paper or a poster, mentored by a faculty member, at a scholarly meeting in the field of RNA research. The Institute for RNA Innovation will provide grants of up to $1,000. Travel Grant awards may also be used for trainings, workshops, or courses in the field of RNA research. Funds may be used for registration fees, transportation, and lodging. Funding will not cover related books, materials, or meals.
Application Requirements and Procedures
Applications will be accepted year-round on a rolling basis. Applications must be submitted at least three weeks prior to the start of travel as a single PDF file.
Please label the file as ApplicantFullName_Travel_SubmissionDate.pdf and include the following materials:
- Complete a brief proposal (no more than 500 words) outlining the nature of the travel request, the level of participation, and need for funds. Applicant should also include up to 3 sentences describing professional goals.
- Letter of support from mentor.
After your submission is complete, you will receive a confirmation receipt by email.
Eligibility and appropriate travel support will be determined by the Institute for RNA Innovation. A committee will review the applications and inform selected applicants within two weeks of submission.
No more than 3 awards will be issued per mentor lab in each fiscal year.
Grant Recipient Reimbursement and Requirements
- Travel claims with receipts must be submitted within 15 days of a student or postdoctoral researcher’s return.
- Airfare must be booked in World Travel/Concur.
- Book AMTRAK directly on www.amtrak.com
- Your award letter will include details about reimbursement.
- Within 15 days of return, provide follow-up information regarding the impact of attendance on research, scholarship, or other professional developmental goals. This includes a short blurb about experience for the news section of the Institute for RNA Innovation website with picture (if available).
Questions?
Contact: Jill Agolino
Apply on-line here.
The AI-driven RNA BioFoundry (AIRFoundry) is pleased to announce a call for proposals for seed grants aimed at advancing innovative research, education, and applications of RNA technologies. These grants are designed to support projects that leverage RNA and/or lipid nanoparticle technology for transformative outcomes across diverse fields of research, including fundamental and basic science, biotechnology, agriculture, sustainability, food science, and animal health. AIRFoundry’s mission is to revolutionize the design, synthesis, and delivery of RNA, democratizing access to these tools for researchers worldwide.
Learn more here.
2025
| Awarded | PI | Title | School | Department | Co-PI(s) | Project Title |
|---|---|---|---|---|---|---|
| 1 | Monica Pomaville, MD (Sponsor: Jessica Foster, MD) | Physician Fellow | Children’s Hospital of Philadelphia | Pediatric Hematology and Oncology | Antisense oligonucleotides targeting fusion oncogenes in pediatric high-grade glioma | |
| 2 | Jilian Melamed, PhD | Research Assistant Professor | Pereleman School of Medicine | Medicine – Infectious Disease | Lesley Chaboub, PhD | Tolerogenic mRNA-LNP Vaccines Encoding Full-Length Myelin Antigens for Antigen-Specific Therapy in Multiple Sclerosis |
| 3 | Aime Franco, PhD | Associate Professor | Children’s Hospital of Philadelphia | Endocrinology & Diabetes | MicroRNAs as Drivers and Diagnostic Markers of DICER1-Mutant Thyroid Tumors | |
| 4 | Daeyeon Lee, PhD | Russell Pearce and Elizabeth Crimian Heuer Professor | School of Engineering and Applied Science | Chemical and Biomolecular Engineering | Kathleen Stebe, PhD and Brian Gregory, PhD | Ambient-Stable, GRAS-Only Deep Eutectic Solvent Formulations for Foliar mRNA Delivery in Plants |
| 5 | Laurel Redding, PhD, VMD | Associate Professor | School of Veterinary Medicine | Epidemiology | Mohamed-Gabriel Alameh, PhD, Joseph Zackular, PhD, and Joy Tomlinson, DVM, PhD |
Safety and immunogenicity of an mRNA-LNP vaccine against Clostridioides difficile in horses |
| 6 | Andrew Zahrt, PhD | Assistant Professor | School of Arts & Sciences | Chemistry | AI/ML-Guided Lead Expansion for Duchenne Muscular Dystrophy (DMD) Therapeutics | |
| 7 | Montserrat Anguera, PhD | Associate Professor | School of Veterinary Medicine | Biomedical Sciences | Andrew Vaughan, PhD | Role of long noncoding RNA Xist in modulating female-specific protective B cell responses to coronavirus infections |
| 8 | Vijay Bhoj, MD, PhD | Assistant Professor | Pereleman School of Medicine | Pathology and Laboratory Medicine | Jilian Melamed, PhD | Ex Vivo and In Vivo Immune Modulation Using mRNA-LNPs To Promote Allograft Tolerance in Solid Organ Transplantation |
| 9 | Qin Li, PhD | Assistant Professor | Pereleman School of Medicine | Genetics | Identification of immunogenic Z-RNAs and regulators of the Z-RNA sensing pathway | |
| 10 | Ross England, MD, PhD | Instructor | Children’s Hospital of Philadelphia | Pediatrics | Establishment of a single-epitope mouse model of maternal antibody interference using mRNA-LNP-encoded monoclonal antibodies | |
| 11 | Barry Cooperman, PhD | Professor | School of Arts & Sciences | Chemistry | New Translational Readthrough Inducing Drugs (TRIDs) for Treatment of PTC Diseases | |
| 12 | Marco Carpenter (Sponsor: Mohamad-Gabriel Alameh, Ph.D.) | Postdoctoral Fellow | Children’s Hospital of Philadelphia | Pediatrics | Optimizing mRNA-LNP payload potency in fetal neurons to cure SMA | |
| 13 | Tejvir Khurana, MD, PhD | Professor | Pereleman School of Medicine | Physiology | Gene Editing for Duchenne Muscular Dystrophy (DMD) Therapeutics |
Application deadline has expired
RNA Pilot Grant Program
Fall 2025
The Penn Institute for RNA Innovation at the University of Pennsylvania, CHOP, and Wistar seeks to support RNA-related basic, translational and clinical research. Towards that goal, the Institute is requesting applications for its Pilot Grants Program for Fall 2025. Pilot funding will provide initial support to establish proof of concept or extend findings to enable extramural funding and publications in the future. Given changes in funding priorities at NIH this Pilot award will also be available for existing RNA-related projects that are being modified to bridge to new scientific areas that align with priority areas of the RNA Institute. These priority areas are indicated below along with, deadlines, and application guidelines.
The Fall 2025 Pilot Grant Program research priority areas will be to support:
- Cross-disciplinary research that will lead to extramurally funded research in either basic or translational science in the arena of RNA biology. Of note, applications related to vaccine research involving RNA continue to be welcomed.
- Supplements to existing projects involving RNA basic or translational science in which a change in direction is planned to align with emerging NIH priorities.
- Early-stage investigators undertaking new projects involving basic or translational RNA technology will be a priority for this RFA.
Prior recipients of pilot awards from the RNA Institute are eligible to apply for new awards in different areas. Prior awardees may also apply for funds to extend research from a previous pilot award and will be judged based on progress made during the first funding period.
Use of the Institute’s shared resource Cores is encouraged and includes the mRNA Core, LNP Core, Targeting Core, and High-throughput Screening Core.
We encourage applicants to consult with our Core Directors or any members of the Institute’s Leadership Group early in the preparation of their application. Allocation of Core effort to assist in grant preparation will be available on a first-come first-served basis.
Scientific areas for applications to address:
RNA Basic Science: RNA processing, RNA binding proteins, noncoding RNAs, and nucleoside-modifications are encouraged along with the development of tools to further the use of RNA technology in the treatment of disease.
Translational Science: RNA-based science relevant to prevention, diagnostics, and therapeutics for human diseases. Projects and teams that bridge laboratory-based research to pre-clinical studies or models and/or that extend clinical observations to the laboratory (addressing mechanisms, identifying therapeutic targets, and developing novel interventions) are strongly encouraged to apply.
We hope you will consider this opportunity to creatively apply RNA-based approaches to new and exciting questions in your research.
Program Timeline
Application Due: October 27, 2025
Decisions/Results Communicated to Applicant: December 2025
Funding of Successful Applicants Begins: January 1, 2026
Eligibility
Principal Investigators (PIs) for awards must have a faculty appointment at the University of Pennsylvania, Children’s Hospital of Philadelphia, or the Wistar Institute and hold the rank of Assistant, Associate or Full Professor, Research Professor, or Instructor. Postdoctoral trainees are also encouraged to apply, provided that a faculty sponsor includes a Letter of Support for the trainee in the application.
Proposals may not describe the same specific research that is funded by other sources during the grant period.
PENN INSTITUTE FOR RNA INNOVATION FALL 2025 PILOT – DETAILED BUDGET
Budget and Duration
Individual applicants may request budgets up to $50,000 in direct costs and may propose projects lasting up to 12 months. The total equipment budget must not exceed $10,000.
Application Requirements and Procedures
Full applications must be uploaded no later than October 27, 2025 as a single PDF file. Please label the file as PIFullName_PilotFall2025.pdf and include the following materials:
- Cover Letter: A brief cover letter from the PI containing the title of the proposal and describing the value of the project and a statement that all collaborators listed on the application agree with the proposal.
- Abstract: A brief abstract of no more than 250 words.
- NIH Biosketch: An NIH format biosketch must be submitted for the PI and Co-Is.
- Proposal: The research proposal should be two single-spaced pages with one-inch margins and should include the essential background information related to the project. Inclusion of preliminary data is welcomed but not required. Please use Arial size 11 font. References should be attached to your research proposal and will not count toward your page limit. Please provide a timeline of implementation to ensure meeting all milestones by the end of the funding period.
- Budget: Please use the template budget page and provide detailed expenses. Salary support for faculty is discouraged.
- Budget Justification: Please provide a short justification for all personnel, supplies, and equipment that will be expensed to this project. Please indicate the importance of this funding to the feasibility of your research proposal. Please indicate if any other funds are available to you for the proposed research.
Applications should be uploaded here. After your submission is complete, you will receive a confirmation receipt by email.
Eligibility and appropriate project support will be determined by the Institute for RNA Innovation. The application must have RNA-related research as its focus and currently not be funded by other sources.
Review Criteria
A peer review panel composed of faculty with a range of expertise will be responsible for award decisions, evaluating eligible applications competitively. The primary factors in award decisions will be the scientific merit of the proposed research and the long-term promise of the proposed research. No critiques will be provided to applicants; applicants will be informed with a review response of “Funded,” “Not funded” or “Not eligible.”
Grant Recipient Requirements
Copies of IACUC and IRB approvals will be required if an award is funded.
Those receiving a grant will be expected to become active members of the Institute for RNA Innovation research community. Both the PIs and those working on funded projects are expected to:
- Acknowledge Institute for RNA Innovation Support in publications. Any publications that are a direct result of this funding must reference: “Supported in part by the Institute for RNA Innovation of the Perelman School of Medicine at the University of Pennsylvania.”
- Self-identify as a member of the Institute for RNA Innovation on all publications emanating from the work supported by this grant.
- Use awarded funds solely to support the RNA research described in their proposal.
- Provide a progress report 30 days after the end of funding.
- Contribute a presentation on research accomplishments at a future talk/symposium hosted by the Institute for RNA Innovation.
- Provide follow-up information regarding the long-term impact of the award(s) on your overall research program and funding.
Questions?
Contact: Jill Agolino
2024
| PI | Title | Contact | School | Department | Project Title |
| Timothy Spear | Instructor of Pedaitrics | speart@chop.edu | Children’s Hospital of Philadelphia | Oncology | In vivo mRNA CAR-lymphocyte manufacturing using novel fractalkine and cytokine receptor targeting lipid nanoparticles for high-risk neuroblastoma |
| Peter Klein, MD, PhD | Professor | pklein@pennmedicine.upenn.edu | Penn School of Medicine | Hematology/Oncology | Splicing and mitochondrial quality control in MDS and CMML |
| Guilem Pascual-Pasto, PhD | Post Doctoral Fellow | pascualpag@chop.edu | Children’s Hospital of Philadelphia | Oncology | GPC2-targeted nanoparticle-encapsulated RB1 mRNA for restoration of the RB1 tumor suppressor function in retinoblastoma |
| Kristopher Bosse, MD | Assistant Professor | bossek@email.chop.edu | Children’s Hospital of Philadelphia | Pediatrics | Development of a GPC2 CAR T cell amplifying RNA vaccine |
| Lijun Zhou, PhD | Assistant Professor | lijun.zhou@pennmedicine.upenn.edu | Penn School of Medicine | Biochemistry & Biophysics | Development of a novel allele-specific gene silencer XNAzyme |
| Marija Drndic, PhD | Professor | drndic@physics.upenn.edu | Penn School of Arts and Sciences | Physics & Astronomy | Solid-state nanopores for characterization and quantitative analysis of mRNA capping efficiency |
| Kathleen O’Neil, MD | Associate Professor | kathleen.o'neill2@pennmedicine.upenn.edu | Penn School of Medicine | Obstetrics & Gynecology | Use of Noninflammatory mRNA-LNP Delivery to Increase Endometrial Secretion of Cytokines Essential for Early Pregnancy |
| Michael Mitchell, PhD | Professor | mjmitch@engineering.upenn.edu | Penn School of Arts and Sciences | Bioengineering | VEGF mRNA Lipid Nanoparticle Platform for Treating Pregnancy Disorders |
| Panteleimon Rompolas, MBA, PhD | Associate Professor | rompolas@pennmedicine.upenn.edu | Penn School of Medicine | Dermatology | mRNA approaches to model and treat skin fibrosis |
| Beverly Davidson, PhD | Professor | davidsonbl@chop.edu | Children’s Hospital of Philadelphia | Pathology | Base Editing for Improving Huntington’s Disease Pathologies |
| Sita Awasthi, PhD | Research Associate Professor | sawasthi@pennmedicine.upenn.edu | Penn School of Medicine | Infectious Diseases | Developing a novel mRNA encoded immuno-therapy for severe herpes diseases |
| PI | Title | Contact | School | Department | Project Title |
| Nikolaos Sgourakis, PhD | Professor | nikolaos.sgourakis@pennmedicine.upenn.edu | Penn School of Medicine | Biochemistry & Biophysics | Exploring MHC-targeted LNP delivery of novel immunotherapies to cold tumors |
| Kristen Lynch, PhD | Professor | klync@pennmedicine.upenn.edu | Penn School of Medicine | Biochemistry & Biophysics | Regulation of IRF7 Splicing to Control Viral Infection |
| Michael Hogan, PhD | Assistant Professor | mihogan@upenn.edu | Penn School of Veterinary Medicine | Pathobiology | Development of mRNA vaccines for fish |
| Andrew Santiago-Frangos, PhD | Assistant Professor | asantia3@sas.upenn.edu | Penn School of Arts and Sciences | Biology | Visualizing DNA quaternary structures that regulate CRISPR adaptation to RNA |
| Wei Guo, PhD | Professor | guowei@sas.upenn.edu | Penn School of Arts and Sciences | Biology | Development of a novel allele-specific gene silencer XNAzyme |
| Amanda Muir, MD, MTR | Associate Professor | muira@email.chop.ed | Children’s Hospital of Philadelphia | Pediatrics | Direct therapeutic targeting of the esophagus: Novel treatment for eosinophilic esophagitis |
2023
| PI | Title | Contact | School | Department | Project Title |
| Ravi Amaravadi, MD | Professor | ravi.amaravadi@pennmedicine.upenn.edu | Penn School of Medicine | Hematology/Oncology | Lysosomal inhibition to enhance RNA expression efficiency from RNA-LNPs |
| Susan Weiss, PhD | Professor | weisssr@pennmedicine.upenn.edu | Penn School of Medicine | Microbiology | Identification of RNA-binding region of coronavirus nonstructural protein (nsp)1 and its influence on protein translation |
| Elizabeth Heller, PhD | Associate Professor | eheller@pennmedicine.upenn.edu | Penn School of Medicine | Pharmacology | Chromatin mediated alternative splicing |
| Taku Kambayashi, MD, PhD | Professor | kambayat@pennmedicine.upenn.edu | Penn School of Medicine | Pathology & Lab Medicine | The role of oocyte RNA in microbiome-induced transgenerational epigenetic inheritance |
| Michael Abt, PhD | Associate Professor | michael.abt@pennmedicine.upenn.edu | Penn School of Medicine | Microbiology | Therapeutic delivery of IL-10 to promote microbiome transplantation success |
| Hongiun Song, PhD | Professor | shongjun@pennmedicine.upenn.edu | Penn School of Medicine | Neurosciences, Biochemistry & Biophysics | Translation inhibition by eIF4A in neurodegeneration |
| Chin Nien Lee, PhD | Senior Research Investigator (Deng lab) | chinnien.lee@pennmedicine.upenn.edu | Penn School of Medicine | Pathology & Laboratory Medicine | Spatial co-profiling of miRNAs, mRNAs, and accessible chromatin in MS lesion |
| Juan Alvarez, PhD | Assistant Professor | juan.alvarez@pennmedicine.upenn.edu | Penn School of Medicine | Cell & Developmental Biology | RNA processing control of human islet maturation by MBLN1 |
| PI | Title | Contact | School | Department | Project Title |
| Kahlilia Morris-Blanco, PhD | Presidential Assistant Professor | kahlilia.blanco@pennmedicine.upenn.edu | Penn School of Medicine | Cell & Developmental Biology | Efficacy and mechanisms of lncRNA delivery to the brain after stroke via lipid nanoparticles |
| Donna Huryn, PhD | Professor of Practice | Huryn@sas.upenn.edu | Penn School of Arts & Sciences | Chemistry | Development of small molecule utrophin up-regulators for the treatment of Duchenne muscular dystrophy (DMD) |
| Jia Nong | Research Associate | iwgpark@gmail.com | Penn School of Medicine | Pharmacology & Translational Therapeutics | Targeted lipid nanoparticles to modulate blood-brain barrier transcytosis in acute ischemic stroke |
| Ivan Dmochowski, PhD | Associate Professor | ivandmo@sas.upenn.edu | Penn School of Arts & Sciences | Chemistry | Development of Novel Duplex Chaperone RNA Oligonucleotides for Duchenne Muscular Dystrophy (DMD) Therapeutics |
| Elizabeth Hennessy | Research Associate | ehenn@pennmedicine.upenn.edu | Penn School of Medicine | Institute for Translational Medicine | Using endothelial cell targeted LNPs to silence an inflammatory long non-coding RNA with antisense oligonucleotides |
| Laurence Eisenlohr, VMD, PhD | Professor | eisenlc@pennmedicine.upenn.edu | Children’s Hospital of Philadelphia | Children’s Hospital of Philadelphia | Basis for mRNA Vaccine Activation of CD4+ T Cells |
| Martin Carroll, MD | Associate Professor | carroll2@pennmedicine.upenn.edu | Penn School of Medicine | Hematology/Oncology | Develop a novel nucleic acid delivery system that circumvents the general complications with pharmacological inhibitors to target DYRK1A as a therapeutic tool for B-ALL therapy |
| Christoph Ellebrecht, MD | Assistant Professor | chell@pennmedicine.upenn.edu | Penn School of Medicine | Dermatology | Modulating Asymmetric Cell Division of Human CAR T Cells through mRNA Delivery |
| Andrew Tsourkas, MS, PhD | Professor | atsourk@seas.upenn.edu | Penn School of Arts & Sciences | Bioengineering | Universal strategy for facile preparation of site-specifically conjugated antibody-targeted lipid nanoparticles |
| Jilian Melamed, PhD | Research Assistant Professor | jilian.melamed@pennmedicine.upenn.edu | Penn School of Medicine | Infectious Diseases | A novel mRNA tolerizing therapy for type 1 diabetes |